SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...
Myriad offers three genetic tests to those who are pregnant ... women between 7-37 weeks gestational age. In a 2021 laboratory test, SneakPeek accurately determined fetal sex in 99.02% of 102 ...
Myriad Genetics, Inc. has launched a new educational ... pregnant women between 7-37 weeks gestational age. In a 2021 laboratory test, SneakPeek accurately determined fetal sex in 99.02% of ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and Trademark Office has issued two new patents that ...
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management ...
Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management ...
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics ... state-of-the-art laboratory facility in Salt Lake City. About Precise Molecular Residual Disease (MRD) Test Myriad’s ...
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics ... company’s state-of-the-art laboratory facility in Salt Lake City. Myriad’s Precise MRD test is whole-genome sequencing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results